Integrated Advisors Network LLC Has $639,000 Position in The Clorox Company (NYSE:CLX)

Integrated Advisors Network LLC raised its position in The Clorox Company (NYSE:CLX) by 98.1% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,338 shares of the company’s stock after purchasing an additional 2,148 shares during the period. Integrated Advisors Network LLC’s holdings in Clorox were worth $639,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of CLX. Norges Bank bought a new stake in shares of Clorox in the 4th quarter valued at $259,041,000. FMR LLC grew its stake in Clorox by 75.4% in the fourth quarter. FMR LLC now owns 1,361,758 shares of the company’s stock valued at $221,163,000 after acquiring an additional 585,526 shares during the period. Marshall Wace LLP grew its stake in Clorox by 549.8% in the fourth quarter. Marshall Wace LLP now owns 542,726 shares of the company’s stock valued at $88,144,000 after acquiring an additional 459,203 shares during the period. ExodusPoint Capital Management LP increased its holdings in shares of Clorox by 187.9% in the fourth quarter. ExodusPoint Capital Management LP now owns 698,900 shares of the company’s stock worth $113,508,000 after acquiring an additional 456,114 shares in the last quarter. Finally, Man Group plc raised its position in shares of Clorox by 154.6% during the fourth quarter. Man Group plc now owns 570,503 shares of the company’s stock worth $92,655,000 after purchasing an additional 346,449 shares during the period. 78.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Clorox

In other news, Director Pierre R. Breber acquired 4,000 shares of the stock in a transaction dated Wednesday, May 7th. The shares were bought at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the purchase, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $546,280. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.57% of the company’s stock.

Clorox Stock Down 3.3%

Shares of CLX stock opened at $123.03 on Friday. The firm’s fifty day moving average price is $134.91 and its two-hundred day moving average price is $148.48. The company has a current ratio of 0.94, a quick ratio of 0.60 and a debt-to-equity ratio of 20.52. The Clorox Company has a 1 year low of $122.84 and a 1 year high of $171.37. The firm has a market capitalization of $15.16 billion, a P/E ratio of 33.61, a PEG ratio of 2.62 and a beta of 0.54.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a net margin of 6.38% and a return on equity of 316.87%. The company had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.74 billion. During the same quarter in the previous year, the business earned $1.71 EPS. Clorox’s revenue was down 8.0% on a year-over-year basis. On average, equities analysts predict that The Clorox Company will post 7.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CLX. JPMorgan Chase & Co. cut their price objective on Clorox from $151.00 to $144.00 and set a “neutral” rating on the stock in a report on Tuesday, May 6th. Evercore ISI set a $140.00 price target on shares of Clorox and gave the company an “underperform” rating in a research note on Tuesday, May 6th. Barclays reduced their price target on shares of Clorox from $134.00 to $129.00 and set an “underweight” rating for the company in a report on Wednesday, May 7th. Morgan Stanley dropped their price objective on shares of Clorox from $165.00 to $150.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 6th. Finally, Citigroup cut their price objective on shares of Clorox from $165.00 to $150.00 and set a “neutral” rating on the stock in a research report on Monday, April 14th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $151.23.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.